CNCR
Loncar Cancer Immunotherapy ETF
Loncar Cancer Immunotherapy TR USD
NAV as of
4 Week: 11.72 - 13.45
52 Week: 11.72 - 19.28
Latest Closing Price
11.86
Premium / Discount
0.13
Expense Ratio
0.79%
Investment Objective
The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -13.62 | 1.61 | -8.44 |
| 1 Day | 1.19 | 0.00 | 0.00 |
| 1 Week | -3.10 | 4.41 | -0.70 |
| 1 Month | -10.63 | 7.48 | -1.42 |
| 3 Months | -13.78 | 13.67 | -1.01 |
| 6 Months | -16.24 | 21.82 | -0.74 |
| 1 Year | -34.69 | 38.89 | -0.89 |
| 2 Years | -59.24 | 50.17 | -1.18 |
| 3 Years | -37.25 | 61.05 | -0.61 |
| 5 Years | -59.89 | 76.20 | -0.79 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | -25.3506 | 13.0974 | -20.2684 | 24.0699 | 36.2193 | -19.4051 | -41.8131 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 98.0000 | 90.0000 | 100.0000 | 55.0000 | 20.0000 | 96.0000 | 98.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| 28/12/2021 | 30/12/2021 | 1.8533 |
| 27/12/2017 | 01/01/2018 | 0.3502 |
Portfolio Data
Total Number of Holdings: 32
Number of Bond Holdings: 0
Number of Equity Holdings: 30
Total Market Value: 17,057,297
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | Merus NV | 6.0001 | 53,056 | 0 | 1,023,450 |
| 2 | Regeneron Pharmaceuticals Inc | 4.5287 | 963 | 0 | 772,480 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 8.29 |
| Large | 21.33 |
| Medium | 11.06 |
| Small | 19.15 |
| Micro | 40.15 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
3.8390
Price/Book*
2.4045
Price/Sales*
2.7843
Price/Cash Flow*
1.9661
Dividend Yield*
0.4979
Growth Measures
Long-Term Earnings
6.7920
Historical Earnings
36.5837
Sales Growth
22.7106
Cash-Flow Growth
35.9578
Book-Value Growth
10.1991
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
